Skip to ContentSkip to Navigation
Practical matters How to find us prof. dr. M. (Michiel) Rienstra

Research interests

Graduated in medicine at the University of Antwerp, Belgium in 2003. Obtained a PhD at the University of Groningen, The Netherlands in 2007 on Atrial Fibrillation, Underlying Disease and Prognosis. I completed my cardiology training at the University Medical Center Groningen in 2012, where continued working as clinical cardiologist and researcher. I was awarded with a NWO Rubicon grant in 2009 and went to Harvard Medical School, Massachusetts General Hospital and the Framingham Heart Study for a post-doc on population genetics and epidemiology in 2010-2011. In 2012 I was awarded with the NWO Veni grant for his project on genetics of atrial fibrillation. In 2015 I received the European Society of Cardiology academic grant for his project on a big data approach in atrial fibrillation. I am work package leader of 4 large national consortia; RACE V (hypercoagulability and AF progression), RED-CVD (early detection of cardiovascular disease in general practices), AI (catalyzing the application of artificial intelligence in CV disease), and MyDigiTwin (Big-data and Artificial Intelligence-based ecosystem to create a user’s personal “Digital Twin”) . I am steering committee member of several investigator-initiated clinical studies (RACE 2 to 7, MARC 1-2, VIP-HF, DECISION). I am fellow of the European Society of Cardiology and the American Heart Association, and Scientific & Clinical Education Lifelong Learning Committee (SCILL) member of the AHA - Genomics and Precision Medicine council.


I combine clinical cardiology focusing on treatment of patients with arrhythmias, with clinical-oriented research. My research consists of conducting clinical studies to improve AF treatment, studying epidemiology of AF and its risk factors in PREVEND, Lifelines and Framingham Heart Study, uncovering the genetics of atrial fibrillation in part with the international AFGen onsortium, and applying novel bioinformatics tools to improve AF risk prediction.

Read more


A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?

Association between comorbidities and left and right atrial dysfunction in patients with paroxysmal atrial fibrillation: Analysis of AF-RISK

Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration

Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study

Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis

Corrigendum to: AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial

Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation

Different circulating biomarkers in women and men with paroxysmal atrial fibrillation: results from the AF-RISK and RACE V studies

Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference

Read more


Targeted therapy effect on sinus rhythm in early AF may not stand the test of time

Vorhofflimmern: Kann Risikofaktor-Management Sinusrhythmus erhalten?

RACE 3: Effects Wane for Targeted Therapy in Early AF, HF

CONNECT magazine

Ik vertrouw op mijn collega's in de regionale ziekenhuizen

Dagblad van het Noorden interview; ‘Samen voor het hart‘

NFU Rapport “Onderzoek en innovatie met en voor de gezonde regio” aangeboden aan minister Bruins, VWS.

Read more